0000899243-18-016599.txt : 20180614 0000899243-18-016599.hdr.sgml : 20180614 20180614160841 ACCESSION NUMBER: 0000899243-18-016599 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180613 FILED AS OF DATE: 20180614 DATE AS OF CHANGE: 20180614 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BJERKHOLT ERIC CENTRAL INDEX KEY: 0001197350 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37519 FILM NUMBER: 18899253 MAIL ADDRESS: STREET 1: 132 PURDURE AVENUE CITY: KENGSINGTON STATE: CA ZIP: 94708 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aimmune Therapeutics, Inc. CENTRAL INDEX KEY: 0001631650 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 452748244 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 8000 MARINA BOULEVARD STREET 2: SUITE 300 CITY: BRISBANE STATE: CA ZIP: 94005-1884 BUSINESS PHONE: (650) 614-5220 MAIL ADDRESS: STREET 1: 8000 MARINA BOULEVARD STREET 2: SUITE 300 CITY: BRISBANE STATE: CA ZIP: 94005-1884 FORMER COMPANY: FORMER CONFORMED NAME: Allergen Research Corp DATE OF NAME CHANGE: 20150123 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-06-13 0 0001631650 Aimmune Therapeutics, Inc. AIMT 0001197350 BJERKHOLT ERIC AIMMUNE THERAPEUTICS, INC. 8000 MARINA BOULEVARD, SUITE 300 BRISBANE CA 94005-1884 0 1 0 0 Chief Financial Officer Common Stock, $0.0001 par value 2018-06-13 4 P 0 1600 30.4144 A 19485 D The transaction was executed in multiple trades in prices ranging from $30.35 to $30.4292, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Includes shares represented by restricted stock units ("RSUs") and will be settled in common stock upon vesting over a specified time, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. Includes 385 shares acquired on May 15, 2018 pursuant to Issuer's employee stock purchase plan. /s/ Douglas T. Sheehy, as Attorney-in-Fact for Eric H. Bjerkholt 2018-06-14